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Research Article
Abstract
Aim: The aim of the present analysis was to compare cardiovascular disease risk factors in patients from 
different countries in Europe, using baseline data from the Liraglutide Effect and Action in Diabetes: Evaluation of 
cardiovascular outcome Results (LEADER) trial.
Methods: Baseline characteristics and treatments were compared between the subgroup of patients with 
established cardiovascular disease included in this study from the Eastern European Union (EEU), Western 
European Union (WEU), and Russia and Serbia (Ru/Se). 
Results: Glycaemic control was similar in the EEU and WEU, and poorest in Ru/Se, although WEU patients 
were older and had longer diabetes duration. Systolic blood pressure was lowest in Ru/Se, whereas diastolic blood 
pressure was lowest in the WEU. Control of dyslipidaemia was best in the WEU, and worst in Ru/Se. The percentage 
of patients meeting all three targets for cardiovascular risk factors (HbA1c: ≤ 64 mmol/mol [8.0%], blood pressure: 
<140/<90 mmHg and low-density lipoprotein [LDL]-cholesterol: 1.8 mmol/L [70 mg/dL]) was 9.7%, 6.4% and 3.2% 
in the WEU, EEU and Ru/Se, respectively. Metformin and sulphonylurea treatment was more frequent in the EEU 
than WEU and Ru/Se. Insulin, in turn, was used less frequently in the EEU than WEU and Ru/Se. The use of newer 
drugs was small and differences could not be subjected to statistical analyses. Statins were used most frequently in 
WEU countries and least frequently in Ru/Se. 
Conclusion: The high cardiovascular risk patients in the WEU were older and had longer diabetes duration, 
when compared with EEU and Ru/Se. Despite this, they had a lower body mass index (BMI), similar blood pressure 
and better lipid control. Although the differences were small, the percentage of patients meeting all three treatment 
targets was low across all regions studied.
Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline 
Characteristics of Eastern and Western European Participants with 
Established Cardiovascular Disease in the LEADER Trial
Franek E1,2*, Rutten GEHM3, Ørsted DD4, Baeres FMM4, Mota M5, Jacob S6, Bain SC7, Vidal J8 and Haluzik M9
1Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland 
2Department of Internal Diseases, Endocrinology and Diabetology, Central Clinical Hospital MSW, Warsaw, Poland
3Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands
4Novo Nordisk, Denmark
5University of Medicine and Pharmacy of Craiova, Romania
6Kardio Metabolischen Instituts, Villingen-‐Schwenninge, Germany
7Institute of Life Science, Swansea, University Medical School, UK
8Universitat de Barcelona, Hospital Clinic Universitari, Barcelona, Spain
9Institute of Endocrinology and Institute of Medical Biochemistry and Laboratory Diagnostics of 1st Faculty of Medicine and General University Hospital, Charles 
University in Prague, Prague, Czech Republic 
*Corresponding author: Prof. Edward Franek, Department of Internal Diseases, 
Endocrinology and Diabetology Central Clinical Hospital MSW, ul. Woloska 137, 
02-507 Warsaw, Poland, Tel: +48225081405; E-mail: Edward.Franek@cskmswia.pl
Received January 11, 2016; Accepted February 10, 2016; Published February 
15, 2016
Citation: Franek E, Rutten GEHM, Ørsted DD, Baeres FMM, Mota M, et al. (2016) 
Leader 8: Type 2 Diabetes Patients: A Comparison of Baseline Characteristics 
of Eastern and Western European Participants with Established Cardiovascular 
Disease in the LEADER Trial. J Diabetes Metab 7: 646. doi:10.4172/2155-
6156.1000646
Copyright: © 2016 Franek E, et al. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Keywords: Diabetes control; Blood pressure; Lipids; European 
Union; Russia; Serbia
Introduction
Diabetes is a global burden. It is predicted that, in 2040, the 
prevalence will reach 642 million patients worldwide [1]. There are, 
however, many regional and national differences in the incidence and 
prevalence of diabetes and associated complications. These differences 
may be partially explained by varying prevalence of obesity, differences 
in age distribution and different health service expenditures. The 45 
years of separation between Western and Eastern Europe, the “iron 
curtain”, has resulted not only in the above-mentioned differences 
(mainly economically driven), but also in distinct differences in the 
cardiovascular disease (CVD) epidemiology, which, in turn, has led to 
differences in life expectancy between these regions [2]. 
 The Czech Republic and Poland joined the European Union (EU) 
in 2004, followed by Romania in 2007. However, major political, social 
and economic changes in these countries began in 1989, increasing 
the living standards of these populations. For example, these changes 
led the gross domestic product in Poland to increase by 382% between 
1995 and 2013 [3] and similar changes in the health expenditure in 
some Eastern EU countries [4]. 
The gross domestic product of the Eastern EU is still much lower 
than that of the ‘core’ EU (countries including Germany, France and 
The Netherlands), but is already close to that of Southern EU countries 
like Greece, Portugal and even Spain [5]. The health service in Eastern 
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EU is improving and it seems to be similar to that of Western EU in 
many areas, although this topic is still an area of debate (e.g. mortality 
after surgery [6,7]). There is also indirect proof for an improvement in 
healthcare delivery in the former communist countries with increasing 
longevity of people living in these areas [8]. 
The Liraglutide Effect and Action in Diabetes: Evaluation of 
cardiovascular outcome Results (LEADER) trial [9] is a cardiovascular 
safety study that in Europe recruited patients with type 2 diabetes 
mellitus (T2DM) and either prior CVD or a high risk of CVD from 
16 EU countries (Austria, Belgium, Czech Republic, Denmark, 
Finland, France, Germany, Greece, Ireland, Italy, The Netherlands, 
Poland, Romania, Spain, Sweden and the United Kingdom), and two 
countries outside the EU (Republic of Russia and Serbia/Montenegro). 
Recruitment started in 2010 and finished in 2012. With the same 
inclusion and exclusion criteria across Europe, the LEADER trial offers 
a unique opportunity to compare patients randomized across Eastern 
and Western Europe.
The aim of this analysis was to compare the baseline demographic, 
anthropometric and biochemical parameters, as well as treatment, of 
patients with T2DM included in the LEADER study across Europe.
Patients and Methods
The LEADER study is an international, randomized, double-
blind, placebo-controlled trial with the primary endpoint of assessing 
the cardiovascular safety of liraglutide in patients with T2DM. The 
study design and aims have been described previously [9]. In brief, 
the LEADER study enrolled two groups of patients, both with a 
glycated hemoglobin (HbA1c) level ≥ 53 mmol/mol ( ≥ 7.0%). One 
group included patients with T2DM ≥ 50 years of age with prior 
CVD, cerebrovascular disease, peripheral vascular disease, chronic 
renal failure or chronic heart failure [9]. The other group consisted of 
patients without prior CVD, ≥ 60 years of age with one or more of the 
following cardiovascular risk factors: microalbuminuria or proteinuria; 
hypertension and left ventricular hypertrophy by electrocardiogram or 
imaging; left ventricular dysfunction by imaging; or ankle-brachial 
index <0.9 [9]. The most important exclusion criteria were: type 1 
diabetes mellitus; use of a glucagon-like peptide 1 receptor agonist, 
dipeptidyl peptidase-4 inhibitor, or insulins other than human neutral 
protamine Hagedorn insulin; use of long-acting analogues or premixed 
insulins within 3 months before screening; acute decompensation of 
glycemic control; and acute coronary or cerebrovascular event 14 days 
before randomisation. The required sample size was calculated and is 
shown in the baseline paper [9]. The trial was powered to demonstrate 
non-inferiority of liraglutide versus placebo in terms of first major 
cardiovascular event, and was designed and conducted according to 
the Declaration of Helsinki and approved by local ethical committees 
[10]. All patients signed a consent form before any study procedure 
was performed. 
As there were only a small number of patients in the European 
cohort who had no prior CVD (n=411), further division of this 
population would have resulted in a sample size too small for 
meaningful analysis; therefore, this analysis was limited to participants 
with prior CVD (n=2845). Race and ethnicity were documented at the 
beginning of the study. Full medical history, anthropometric measures 
and HbA1c, serum creatinine, high-density lipoprotein (HDL)-and low-
density lipoprotein (LDL)-cholesterol and triglyceride concentrations 
were obtained, as well as urine samples for albumin/creatinine ratios. 
All samples were obtained after 12 hours of fasting and sent to a central 
laboratory for analysis. Estimated glomerular filtration rate (eGFR) was 
calculated based on the Modification of Diet in Renal Disease equation 
[11].
For the purpose of this analysis, European countries were divided 
into different strata: the Eastern EU was defined as the Czech Republic, 
Poland and Romania. The Republic of Russia and Serbia/Montenegro 
were combined due to insufficient numbers of participants (Russia/
Serbia) and analysed as a separate category. The Western EU 
comprised Austria, Belgium, Denmark, Finland, France, Germany, 
Greece, Ireland, Italy, The Netherlands, Spain, Sweden and the United 
Kingdom. Western EU was additionally divided into the ‘core EU’ 
(Austria, Belgium, France, Germany, Ireland, The Netherlands and 
the United Kingdom), Scandinavia (Denmark, Finland and Sweden) 
and the Southern EU (Greece, Italy and Spain). By further subdividing 
the Western EU data, regions with similar healthcare systems could 
be compared. The sub-regional data are provided as supplementary 
material only (see Supplementary Material).
For this study, targets for metabolic control were defined and 
the proportion of participants achieving target at baseline was 
recorded. The on-target values for HbA1c were ≤ 64 mmol/mol 
(8.0%) and ≤ 53 mmol/mol (7.0%). These values were based on 
American Diabetes Association/European Association for the Study 
of Diabetes as well as local guidelines [12,13]. The target for LDL-
cholesterol was <1.8 mmol/L (70 mg/dL). 
Targets for hypertension treatment were defined as follows: a 
systolic blood pressure (SBP) <140 mmHg and a diastolic blood 
pressure (DBP) <90 mmHg [14], or a more stringent DBP target 
of <80mmHg [14]. Resistant hypertension was defined as the 
prescription of four or more antihypertensive agents at baseline (or 
the prescription of three or more agents for those with blood pressure 
≥ 140/90 mmHg) [15]. A combined composite target was defined 
as the percentage of patients achieving all three target values for 
the key cardiovascular risk factors (HbA1c: ≤ 64 mmol/mol [8.0%], 
blood pressure: <140/90 mmHg and LDL-cholesterol: <1.8 mmol/L 
[70 mg/dL]). An additional, more stringent, composite target was 
also examined, defined as HbA1c ≤ 53 mmol/mol ( ≤ 7.0%), blood 
pressure <140/80 mmHg; LDL-cholesterol <1.8 mmol/L (70 mg/
dL).
Use of medication at baseline was coded using Anatomical 
Therapeutic Chemical (ATC) Classification System codes [16]. 
Antihypertensive medication codes were C02, C07, C08 and 
C09. Oral antidiabetic drugs (OADs) were coded as: metformin, 
A10BA; sulphonylurea, A10BB; glucosidase inhibitors, A10BF; 
thiazolidinediones, A10BG; other OADs, A10BX; combination OAD, 
A10BD; and insulin, A10A. Information on statin use was defined by 
ATC code C10A, and acetylsalicylic acid by drug names ‘acetylsalicylate 
lysine’ or ‘acetylsalicylic acid’.
Statistical Analysis 
Distributions are described by mean (standard deviation) and 
median frequencies and percentages (%) for categorical variables. The 
variation across EU sub-regions of continuous variables was assessed 
using one-way analysis of variance, whereas for categorical variables 
or factors, the chi-square or Fisher’s exact test was used. A two-sided 
p-value <0.01 was considered statistically significant. All analyses were 
performed using SAS version 9.3 (SAS Institute, Cary, NC, USA). 
Analyses were performed using data available at the time, prior to the 
end of the study. 
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Results
Comparisons of patients from the Eastern and Western EU and 
Russia/Serbia are shown in (Tables 1 and 2). These comparisons 
highlighted the differences in age and diabetes duration between the 
European regions (Table 1). Participants from the Western EU were 
older, with a mean age of 65.9 years, compared with the Eastern EU 
and Russia/Serbia (62.1 and 60.8 years, respectively) (Table 1). Western 
EU participants also had a longer history of diabetes and lower body 
mass index (BMI) than the other regions (diabetes duration: 12.4 ± 7.7 
compared with 9.5 ± 6.7 and 9.0 ± 6.0 years for the Eastern EU and 
Russia/Serbia, respectively; BMI: 32.6 ± 5.7 vs. 33.7 ± 5.9 and 34.1 ± 
5.8 kg/m2). Mean HbA1c did not significantly differ between the regions 
(67–69 mmol/mol [8.3–8.5%]).
A similar proportion of participants across the regions met 
the blood pressure target of <140/90 mmHg (Figure 1). Mean 
SBP levels were similar between the Eastern and Western EU and 
slightly lower in Russia/Serbia. DBP levels were lowest in Western 
EU participants (77.4 ± 10.5 compared to 81.3 ± 9.5 and 82.3 ± 8.1 
mmHg for Eastern EU and Russia/Serbia, respectively) (p<0.0001 
vs. Eastern EU). Control of dyslipidaemia was most rigorous in the 
Western EU (mean levels at baseline: LDL: 2.2 ± 0.8 mmol/L; HDL: 
1.16 ± 0.32 mmol/L; triglycerides: 2.1 ± 1.5 mmol/L) and poorest in 
Russia/Serbia (LDL: 3.0 ± 1.0 mmol/L; HDL: 1.18 ± 0.31 mmol/L; 
triglycerides: 2.5 ± 1.9 mmol/L).
The percentage of patients achieving the composite treatment target 
(HbA1c, blood pressure and LDL-cholesterol) did not exceed 10% in any 
region (Table 1; Figure 1). The percentage of patients achieving LDL-
cholesterol targets in the Western EU was 3.6-fold greater than in Russia/
Serbia (Figure 1). When the more stringent targets (HbA1c <53 mmol/mol 
[<7.0%] and blood pressure <140/80 mmHg) were applied, the percentage 
of patients on target was lower than 2% across the whole of Europe, except 
in Scandinavia (2.4%, see Supplementary Table 1). 
Although the number of current smokers was similar across Europe, 
the number of patients who had never smoked was highest (60.1%), 
and previous smokers lowest (28.2%), in Russia/Serbia (Table 1). There 
were also some differences in the proportion of previous smokers and 
those who have never smoked in the Scandinavian, southern and ‘core’ 
EU countries (see Supplementary Table 1).
With regard to medications at baseline, the proportion of 
participants treated with metformin was similar across Europe (82.3% 
vs. 78.2% and 79%, for Western EU, Eastern EU and Russia/Serbia, 
respectively). Use of oral OADs differed considerably between the 
regions. This was even more distinct in the case of sulphonylureas, 
which were administered least frequently in the Western EU (36.3% 
compared with 63.5% and 72.3% of patients from the Eastern EU and 
Russia/Serbia, respectively). The differences in newer drug classes 
were not assessed in terms of significance of difference because of the 
small numbers of patients on these drugs. Insulin was used less often 
in the Eastern EU than in the Western EU and Russia/Serbia (Table 
2). Statins, in turn, were used least frequently in Russia/Serbia and 
most frequently in the Western EU (48.7% and 83.8% of patients, 
respectively; see Table 2).
Discussion
The main finding of this study is that there are small but noteworthy 
regional differences on important parameters between participants 
from the Eastern and Western EU and from Russia/Serbia in the 
LEADER trial. 
Parameter Western EU (1905) Eastern EU (564) Russia and Serbia (Ru/Se) (n=376)
p-value, Eastern EU 
vs. Ru/Se
p-value, Eastern EU 
vs. Western EU
Age [y] 65.9  ± 7.5 62.1 ± 6.9 60.8  ± 6.4 <0.01 <0.0001
Gender, male [n (%)] 1400 (73.5) 344 (61) 162 (43.1) <0.0001 <0.0001
BMI [kg/m2] 32.6  ± 5.7 33.7  ± 5.9 34.1  ± 5.8 NS <0.0001
Diabetes duration [y] 12.4  ± 7.7 9.5  ± 6.7 9.0  ±  6.0 NS <0.0001
HbA1c [mmol/mol (%)] 67 ± 14 (8.3 ± 1.3) 67  ± 14 (8.3  ± 1.3) 69  ± 14 (8.5  ± 1.3) NS NS
Systolic BP [mmHg] 140.8  ± 19.0 140.1  ± 15.8 137.3  ± 14.0 <0.01 NS
Diastolic BP [mmHg] 77.4  ± 10.5 81.3  ± 9.5 82.3  ± 8.1 NS <0.0001
eGFR (MDRD) [ml/min/m2] 77.7  ± 27.1 88.2  ± 24.5 89.3  ± 20.2 NS <0.0001
Albumin/creatinine ratio [mg/mmol] 18.2  ± 62.0 8.8  ± 29.7 6.2  ± 16.0 NS <0.01
LDL-cholesterol [mmol/l] 2.2  ± 0.8 2.5  ±  0.9 3.0 ±1.0 <0.0001 <0.0001
HDL-cholesterol [mmol/l] 1.16  ± 0.32 1.19  ± 0.31 1.18  ± 0.31 NS NS
Triglycerides [mmol/l] 2.1  ± 1.7 2.3  ± 2.1 2.5  ± 1.9 NS NS
Current smokers [n (%)] 252 (13.2) 67 (11.9) 44 (11.7) NS NS
Previous smokers [n (%)] 1087 (57.1) 244 (43.3) 106 (28.2) <0.0001 <0.0001
Never smoked [n (%)] 566 (29.7) 253 (44.9) 226 (60.1) <0.0001 <0.0001
BP above 140/80 mmHg [n (%)] 1243 (65.2) 406 (72) 283 (75.3) NS <0.01
BP above 140/90 mmHg [n (%)] 1004 (52.8) 309 (54.8) 187 (49.7) NS NS
LDL-cholesterol above target [n (%)] 1121 (58.8) 412 (73) 306 (81.4) <0.0001 <0.0001
HbA1c >64 mmol/mol (8%) [n (%)] 883 (46.4) 282 (50.0) 222 (59.0) <0.01 NS
HbA1c >53 mmol/mol (7%) [n (%)] 1735 (91.1) 510 (90.4) 344 (91.5) NS NS
On all 3 targets (less stringent) [n (%)] 185 (9.7) 36 (6.4) 12 (3.2) NS NS
On all 3 targets (more stringent) [n (%)] 29 (1.5) 4 (0.7) 1 (0.3) NS NS
BMI: Body mass index; BP: Blood pressure; eGFR: Estimated glomerular filtration rate; EU: European Union; HDL: High-density lipoprotein; LDL: Low-density 
lipoprotein; MDRD: Modification of Diet in Renal Disease; NS: Not significant; Ru/Se: Russia/Serbia; SD: Standard deviation.
Table 1: Comparison of basal demographic, anthropometric and biochemical parameters between patients with prior cardiovascular disease in the Western and Eastern 
EU, and in Russia/Serbia. Data shown as mean ± SD or n (%).
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Dyslipidaemia control and treatment
The percentage of patients achieving LDL-cholesterol targets was 
lowest in Russia/Serbia, and highest in the Western EU (Figure 1). This 
cannot be explained by different treatment targets set by guidelines in 
Russia/Serbia, as these countries have not issued specific guidelines; 
and for the most likely used guidelines, the target LDL-cholesterol 
for prior CVD patients was <1.8 mmol/L (70 mg/dL) in the LEADER 
recruitment period [12] and later on [17]. A possible explanation is that 
it is due to the less frequent use of statins in Russia/Serbia in comparison 
with the EU countries. Therefore, the percentage of patients below 
target could reflect the number of those who are treated. Again, this 
may not be a result of guideline recommendations, but could instead 
be due to socio-economic circumstances. The latter is supported by the 
 
Figure 1: Percentage of patients meeting treatment targets: BP <140/90 mmHg, LDL-cholesterol <1.8 mmol/l and HbA1c ≤64 mmol/mol (≤8.0%) and all 
three targets together. BP, blood pressure; EU, European Union; HbA1c, glycated haemoglobin; LDL, low-density lipoprotein. 
Parameter Eastern EU (564)
Russia and Serbia 
(Ru/Se) (n=376) Western EU (1905)
p-value, Eastern EU vs. 
Ru/Se
p-value, Eastern EU vs. 
Western EU
Metformin 464 (82.3) 297 (79) 1489 (78.2) NS NS
Sulphonylureas 358 (63.5) 272 (72.3) 692 (36.3) <0.01 <0.0001
Thiazolidinedione 12 (2.1) 2 (0.5) 86 (4.5) NS NS
Alpha-glucosidase inhibitors 53 (9.4) 1 (0.3) 18 (0.9) <0.0001 <0.0001
Other OADs* 0 (0) 2 (0.5) 144 (7.6) NS <0.0001
Fixed combinations of OADs* 4 (0.7) 22 (5.9) 16 (0.8) <0.0001 NS
Insulin treatment [n (%)] 131 (23.2) 133 (35.4) 845 (44.4) <0.0001 <0.0001
No. of antihypertensive 
medications:
0 
1 
2 
3 
4 
35 (6.2)
118 (20.9)
252 (44.7)
125 (12.2)
34 (6.0)
5 (1.3)
98 (26.1)
204 (54.3)
56 (14.9)
13 (3.5)
132 (6.9)
496 (26.0)
839 (44.0)
340 (17.8)
98 (5.1)
<0.0001 NS
Resistant hypertension [n (%)] 111 (19.7) 47 (12.5) 294 (15.4) <0.01 NS
Statin use [n (%)] 425 (75.4) 183 (48.7) 1597 (83.8) <0.0001 <0.0001
Acetylsalicylic acid use [n (%)] 375 (66.5) 182 (48.4) 1285 (67.5) <0.0001 NS
*The use of dipeptidyl peptidase-4 inhibitors was not permitted in the LEADER study.
EU: European Union; NS: Not significant; OAD: Oral antidiabetic drug; Ru/Se: Russia/Serbia. Resistant hypertension defined as the use at baseline of at least four different 
antihypertensives (or the prescription of three or more agents for those with blood pressure  ≥ 140/90 mmHg).
Table 2: Comparison of antidiabetic, antihypertensive and statin treatments in patients with prior cardiovascular disease from Western and Eastern EU, and from Russia/
Serbia. Data shown as n (%).
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fact that the Western EU, as the richest region, was also the region with 
the highest percentage of patients taking statins. 
Despite the fact that, in the EU, reimbursement is most often provided 
by government or national healthcare plans, about 20% of patients with a 
history of CVD are not treated with a statin, and even in the Western EU, 
only about 40% of patients are at LDL target (1.8 mmol/L; approximately 
50% of those treated with statins). Taking into account the high 
cardiovascular risk of that population and the role of LDL-cholesterol as a 
cardiovascular risk factor, this is an important clinical challenge. However, 
comparable results are achieved in similar populations across Europe [18]. 
The percentage of patients on target is much higher than it was 20 years ago 
[18], but similar (at least in the Eastern EU) to the values observed in 2004 
[19], which suggests that in the Eastern EU, most of the improvements 
occurred before joining the EU.
Hypertension control and treatment
Blood pressure levels were similar in different regions across 
Europe, although SBP was lowest in Russia/Serbia and DBP lowest in 
the Western EU. The number of patients with resistant hypertension 
was lowest in Russia/Serbia (and in Southern EU), whereas it was 
highest in Eastern EU. Interestingly, the percentage of patients at blood 
pressure target was also lowest in Russia/Serbia (highest in Western 
EU).
Taken together, blood pressure targets were not reached by a high 
proportion of participants in the remaining regions of the EU. This 
is in accordance with previous results, such as those reported from 
the BP-CARE (blood pressure control rate and cardiovascular risk 
profile) study, which found that blood pressure levels in Eastern and 
Central European countries (Albania, Bosnia, Czech Republic, Latvia, 
Romania, Serbia, Slovakia and Ukraine) averaged 150/90 mmHg, with 
only 27.1% achieving blood pressure control of <140/90 mmHg [20]. 
Additionally, prior to the introduction of more stringent blood pressure 
control targets, the World Health Organization’s MONICA project 
(monitoring trends and determinants in cardiovascular disease), which 
compared blood pressure levels in Western, Northern, Southern and 
Eastern (Poland, Lithuania and Serbia) Europe, yielded levels ranging 
from 130–140 mmHg in all regions [21,22]. 
Interestingly, there were no large numerical differences in the use 
of antihypertensive medications between the regions.
T2DM control and management
The percentage of patients treated with metformin at baseline was 
similar across the regions (Table 2), and in the Eastern EU it is about 
30% higher than reported in 2004 [19]. However, sulphonylureas are 
used much more frequently in the Eastern EU. That may be partially 
explained by more frequent use of other OADs in the Western EU 
(7.6% of participants vs. 0% and 0.5% for Eastern EU and Russia/Serbia, 
respectively), with the exception of the alpha-glucosidase inhibitor, 
which is more frequently used in the Eastern EU (although not in 
Russia/Serbia). However, the differences in OAD treatment could be 
explained by an earlier start of insulin treatment in the Western EU than 
in the Eastern EU, as the percentage of patients treated with insulin was 
highest in the Western EU. In this regard, consideration should also be 
given to the exclusion criteria of this trial, which would have excluded 
patients using dipeptidyl peptidase-4 inhibitors within 3 months prior 
to screening [9]. Data from the SAVOR-TIMI 53 also showed a greater 
percentage of patients treated with insulin in the Western EU than in 
the Eastern EU, although the difference in that trial was only 5% [23]. 
Another possible explanation is the longer duration of diabetes in the 
Western EU (Table 1), potentially resulting from earlier diagnosis due 
to better access to healthcare; this would have increased the percentage 
of insulin-treated patients, even if insulin had been started at the same 
time. Other reasons, like pricing of insulin, may also play a role. In 
spite of those differences, the percentage of patients below target HbA1c 
( ≤ 64 mmol/mol [8.0%]) was similar between Eastern and Western 
EU (50.0% vs. 53.6%, respectively); a lower proportion of patients in 
Russia/Serbia was below target (41.0%). Overall, it seems that, in spite 
of differences in diabetes treatment and the costs of those treatments 
[24] between European regions, metabolic control is similar across 
Europe and remains relatively unsatisfactory, especially if the target is 
considered to be an HbA1c value of ≤ 53 mmol/mol (7.0%) (Table 1). 
Combined target for HbA1c, blood pressure, and LDL
As shown in Table 1 and Supplementary Table 1, only a small 
population of LEADER patients across Europe achieved all three 
goals of treatment, regardless of whether less or more stringent targets 
were taken into account (see ‘Patients and methods’ for details). The 
differences between the regions may be significant, but they are not 
of great importance when we consider that the percentage of patients 
achieving all three targets does not exceed 10% in any country or region 
of Europe in what is a specifically high cardiovascular risk population 
Figure 1).
Albuminuria and kidney function
Albuminuria, measured as albumin/creatinine ratio, was lowest in 
Russia/Serbia but also low in the Eastern EU countries. In contrast, in 
the Western EU it was twice as high, although the mean value did not 
exceed 20 mg/mmol. Kidney function (measured as eGFR) was also 
lowest in the Western EU, although this does not necessarily mean that 
the prevalence of diabetic kidney disease is higher in the Western EU, 
but rather it may reflect the older age of patients and longer duration of 
diabetes treatment in that region. 
Smoking 
While the number of current smokers included in the study was 
similar across all European regions, there were significantly more 
patients who had never smoked and fewer former smokers in Russia/
Serbia compared to the Western and Eastern EU.
These results are in contrast to previously published data. Zatoński 
et al. performed a ‘Closing the Gap’ project [25], which compared the 
numbers of current, former and ‘never’ smokers in different European 
countries, showing the highest percentage of smoking men in Russia 
(aged 20–64 years = 66.2%, although only 20.4% of women). This 
difference in proportions between the two studies could be explained 
by the likelihood that, in patients with established CVD, the number of 
individuals who have already stopped smoking is higher. 
Furthermore, McKee et al. observed that 20 years ago, smoking 
rates in Russian men were very high compared to those in women [26]. 
The Russian/Serbian population enrolled in the LEADER trial includes 
a higher proportion of women (56.9%), which may further explain 
the high numbers of non-smokers and former smokers seen. Another 
possibility is a higher death rate for patients with established CVD in 
these countries [27], leading to inclusion of those who have survived.
Limitations
The study sample is not representative of the general T2DM 
population. Instead, it includes patients with established CVD, 
recruited from diabetology and cardiology (mostly outpatients) units to 
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partake in an international randomized controlled trial. Consequently, 
these patients do not necessarily represent the underlying population, 
making it difficult to ascertain differences between geographic regions 
with respect to participants’ characteristics and health. Additionally, 
the stringent inclusion/exclusion criteria used in the LEADER study 
limit the extrapolation of findings to other populations. We can only 
speculate about the reasons for the differences between EU regions, 
as the LEADER study was not designed for this analysis. Factors that 
were not assessed, but could have impacted the described observations 
include differences in the genetic predispositions of participants to 
CVD, and the implementation of exercise and diet programmes. 
Similarly, differences in the care patterns and healthcare systems and 
costs, as well as availability and obtainability of treatments in each 
participating country are of importance. Moreover, the ‘no prior CVD’ 
group would have been a useful population to analyze; unfortunately, 
the sample size (n=411) made this investigation unfeasible. Further 
investigations using cross-sectional surveys, patient registries, medical 
records or population-based longitudinal studies would prove useful in 
confirming differences between geographical regions.
Conclusions
LEADER patients with established CVD in the Western EU were, 
on average, older and with longer duration of diabetes, but had lower 
BMI and were better controlled in terms of hypertension and LDL-
cholesterol levels compared with participants from the Eastern EU and 
Russia/Serbia. While the observed differences were generally small, 
it is important to note that the percentage of patients at a combined 
target for HbA1c, blood pressure and LDL-cholesterol at baseline did 
not exceed 10% in any region of Europe.
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